123 related articles for article (PubMed ID: 2328211)
1. Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.
Maitland JA; Millar BC; Bell JB; Montes A; Treleaven J; Gore ME; McElwain TJ
Br J Cancer; 1990 Mar; 61(3):429-33. PubMed ID: 2328211
[TBL] [Abstract][Full Text] [Related]
2. Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone.
Bell JB; Millar BC; Maitland JA; Nandi A; Gore M; McElwain TJ
Lancet; 1988 Oct; 2(8617):931-3. PubMed ID: 2902382
[TBL] [Abstract][Full Text] [Related]
3. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
Bell JB; Millar BC; Montes-Borinaga A; Joffe JK; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain TJ
Hematol Oncol; 1990; 8(6):347-53. PubMed ID: 2286358
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ
Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro.
Borinaga AM; Millar BC; Bell JB; Joffe JK; Millar JL; Gooding R; Riches P; McElwain TJ
Br J Haematol; 1990 Dec; 76(4):476-83. PubMed ID: 2265109
[TBL] [Abstract][Full Text] [Related]
6. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
[TBL] [Abstract][Full Text] [Related]
7. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
Forgeson GV; Selby P; Lakhani S; Zulian G; Viner C; Maitland J; McElwain TJ
Br J Cancer; 1988 Oct; 58(4):469-73. PubMed ID: 3207601
[TBL] [Abstract][Full Text] [Related]
8. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
Millar BC; Bell JB; Barfoot R; Everard M
Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
[TBL] [Abstract][Full Text] [Related]
10. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of multiple myeloma].
Golenkov AK
Sov Med; 1991; (3):43-6. PubMed ID: 1882290
[No Abstract] [Full Text] [Related]
12. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
13. [Polychemotherapy in multiple myeloma. The COMPA protocol].
Vázquez-Villegas V; Delgado Lamas JL; Romero-García F; Rodríguez-Carrillo J; Medina-Ruiz F
Rev Invest Clin; 1989; 41(4):345-50. PubMed ID: 2698501
[TBL] [Abstract][Full Text] [Related]
14. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft.
Sirohi B; Powles R; Rudin C; Singhal S; Kulkarni S; Saso R; Horton C; Mehta J; Treleaven J
Hematology; 2005 Oct; 10(5):361-4. PubMed ID: 16203605
[TBL] [Abstract][Full Text] [Related]
15. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
16. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
17. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
[TBL] [Abstract][Full Text] [Related]
18. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression.
Somers LJ; Shaw B; Lyn BE; McMillan AM; Mahendra P
Clin Lab Haematol; 1998 Jun; 20(3):189-90. PubMed ID: 9681237
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
20. Intensive treatment of multiple myeloma and criteria for complete remission.
Gore ME; Selby PJ; Viner C; Clark PI; Meldrum M; Millar B; Bell J; Maitland JA; Milan S; Judson IR
Lancet; 1989 Oct; 2(8668):879-82. PubMed ID: 2571812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
